# Study of the Safety and Efficacy of REGN1033 (SAR391786) in Patients With Sarcopenia

> **NCT01963598** · PHASE2 · COMPLETED · sponsor: **Regeneron Pharmaceuticals** · enrollment: 253 (actual)

## Conditions studied

- Sarcopenia

## Interventions

- **DRUG:** REGN1033 (SAR391786)
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT01963598
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-11
- **Primary completion:** 2015-01
- **Final completion:** 2015-02
- **Target enrollment:** 253 (ACTUAL)
- **Last updated:** 2016-03-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01963598

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01963598, "Study of the Safety and Efficacy of REGN1033 (SAR391786) in Patients With Sarcopenia". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01963598. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*